Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162889 · ClinicalTrials.gov registry record · Phase 1
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01162889 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 70 participants.
The verdict
NCT01162889, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people. One third of the participants will be given an injection or infusion of placebo (sugar water). All participants will be healthy people.
Interventions
- DRUG Placebo SC Injection
- DRUG ATR-107 (PF-05230900) SC Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01162889
The ClinicalTrials.gov registry entry for NCT01162889 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo SC Injection is the first listed.
NCT01162889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01162889 about?
NCT01162889 is a clinical study titled "Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People". This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people. One third of the participants will be given an injection or infusion of placebo...
What is the current status of trial NCT01162889?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2010-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01162889?
The interventions under investigation include: Placebo SC Injection (DRUG), ATR-107 (PF-05230900) SC Injection (DRUG).
Who is sponsoring clinical trial NCT01162889?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.